Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: May, 2016 | Pages:
119 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Diabetic Neuropathy - Pipeline Review, H1 2016 Summary Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Neuropathy pipeline landscape. The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy - The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects - The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Diabetic Neuropathy Overview 9 Therapeutics Development 10 Pipeline Products for Diabetic Neuropathy - Overview 10 Pipeline Products for Diabetic Neuropathy - Comparative Analysis 11 Diabetic Neuropathy - Therapeutics under Development by Companies 12 Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes 14 Diabetic Neuropathy - Pipeline Products Glance 15 Late Stage Products 15 Clinical Stage Products 16 Early Stage Products 17 Diabetic Neuropathy - Products under Development by Companies 18 Diabetic Neuropathy - Products under Investigation by Universities/Institutes 20 Diabetic Neuropathy - Companies Involved in Therapeutics Development 21 Achelios Therapeutics, Inc. 21 Araim Pharmaceuticals, Inc. 22 Celgene Corporation 23 Commence Bio, Inc. 24 Glenmark Pharmaceuticals Ltd. 25 Glucox Biotech AB 26 Kineta, Inc. 27 Lpath, Inc. 28 Neuralstem, Inc. 29 NovaLead Pharma Pvt. Ltd. 30 Omeros Corporation 31 PhiloGene, Inc. 32 Reata Pharmaceuticals, Inc. 33 Relief Therapeutics S.A. 34 Sucampo Pharmaceuticals, Inc. 35 Sumitomo Dainippon Pharma Co., Ltd. 36 ViroMed Co., Ltd. 37 Diabetic Neuropathy - Therapeutics Assessment 38 Assessment by Monotherapy Products 38 Assessment by Target 39 Assessment by Mechanism of Action 41 Assessment by Route of Administration 43 Assessment by Molecule Type 45 Drug Profiles 47 atexakin alfa - Drug Profile 47 Product Description 47 Mechanism of Action 47 R&D Progress 47 benfotiamine - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 BNV-222 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 cibinetide - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 CMB-200 - Drug Profile 54 Product Description 54 Mechanism of Action 54 R&D Progress 54 Cyndacel-M - Drug Profile 56 Product Description 56 Mechanism of Action 56 R&D Progress 56 Flexicaine Peel - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 GRC-17536 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 ketoprofen - Drug Profile 60 Product Description 60 Mechanism of Action 60 R&D Progress 60 Lpathomab - Drug Profile 61 Product Description 61 Mechanism of Action 61 R&D Progress 61 Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile 63 Product Description 63 Mechanism of Action 63 R&D Progress 63 ND-07 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 NLP-198 - Drug Profile 66 Product Description 66 Mechanism of Action 66 R&D Progress 66 NSI-566 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 OMS-721 - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 PDA-002 - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 pirenzepine hydrochloride - Drug Profile 74 Product Description 74 Mechanism of Action 74 R&D Progress 74 ranirestat - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile 76 Product Description 76 Mechanism of Action 76 R&D Progress 76 RTA-901 - Drug Profile 78 Product Description 78 Mechanism of Action 78 R&D Progress 78 RTU-1096 - Drug Profile 79 Product Description 79 Mechanism of Action 79 R&D Progress 79 Small Molecule for Pain - Drug Profile 80 Product Description 80 Mechanism of Action 80 R&D Progress 80 Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile 81 Product Description 81 Mechanism of Action 81 R&D Progress 81 Small Molecules for Diabetic Neuropathy - Drug Profile 82 Product Description 82 Mechanism of Action 82 R&D Progress 82 Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 83 Product Description 83 Mechanism of Action 83 R&D Progress 83 U-2902 - Drug Profile 84 Product Description 84 Mechanism of Action 84 R&D Progress 84 VM-202 - Drug Profile 86 Product Description 86 Mechanism of Action 86 R&D Progress 86 Diabetic Neuropathy - Recent Pipeline Updates 88 Diabetic Neuropathy - Dormant Projects 108 Diabetic Neuropathy - Discontinued Products 112 Diabetic Neuropathy - Product Development Milestones 113 Featured News & Press Releases 113 Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition 113 Sep 17, 2014: Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study 114 Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab 115 May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications 115 Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial 116 Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy 116 Sep 29, 2005: Dainippon And Eisai Signs Licensing Agreement For A Potential New Treatment For Diabetic Neuropathy 116 Appendix 118 Methodology 118 Coverage 118 Secondary Research 118 Primary Research 118 Expert Panel Validation 118 Contact Us 118 Disclaimer 119
List of Tables
Number of Products under Development for Diabetic Neuropathy, H1 2016 10 Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Late Stage Development, H1 2016 15 Comparative Analysis by Clinical Stage Development, H1 2016 16 Comparative Analysis by Early Stage Development, H1 2016 17 Products under Development by Companies, H1 2016 18 Products under Development by Companies, H1 2016 (Contd..1) 19 Products under Investigation by Universities/Institutes, H1 2016 20 Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H1 2016 21 Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H1 2016 22 Diabetic Neuropathy - Pipeline by Celgene Corporation, H1 2016 23 Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H1 2016 24 Diabetic Neuropathy - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 25 Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H1 2016 26 Diabetic Neuropathy - Pipeline by Kineta, Inc., H1 2016 27 Diabetic Neuropathy - Pipeline by Lpath, Inc., H1 2016 28 Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H1 2016 29 Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016 30 Diabetic Neuropathy - Pipeline by Omeros Corporation, H1 2016 31 Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H1 2016 32 Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H1 2016 33 Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H1 2016 34 Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016 35 Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 36 Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2016 37 Assessment by Monotherapy Products, H1 2016 38 Number of Products by Stage and Target, H1 2016 40 Number of Products by Stage and Mechanism of Action, H1 2016 42 Number of Products by Stage and Route of Administration, H1 2016 44 Number of Products by Stage and Molecule Type, H1 2016 46 Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016 88 Diabetic Neuropathy - Dormant Projects, H1 2016 108 Diabetic Neuropathy - Dormant Projects (Contd..1), H1 2016 109 Diabetic Neuropathy - Dormant Projects (Contd..2), H1 2016 110 Diabetic Neuropathy - Dormant Projects (Contd..3), H1 2016 111 Diabetic Neuropathy - Discontinued Products, H1 2016 112
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
